We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Federal Court Upholds Novartis’s Patent for Gilenya
Federal Court Upholds Novartis’s Patent for Gilenya
A federal court in Delaware has ruled that Novartis Pharmaceuticals’ patent for its best-selling multiple sclerosis drug Gilenya (fingolimod) is valid, and HEC Pharm has infringed on it.